In a report released yesterday, Catherine Schulte from Robert W. Baird reiterated a Buy rating on Natera (NASDAQ: NTRA), with a price target of $26. The company’s shares opened today at $24.07, close to its 52-week high of $25.63.
According to TipRanks.com, Schulte is a 5-star analyst with an average return of 25.5% and a 75.3% success rate. Schulte covers the Healthcare sector, focusing on stocks such as Bio-Techne Corporation, Oxford Immunotec, and NanoString Tech.
Currently, the analyst consensus on Natera is a Strong Buy with an average price target of $26.60, implying a 10.5% upside from current levels. In a report released today, Piper Jaffray also maintained a Buy rating on the stock with a $27 price target.
.
See today’s analyst top recommended stocks >>
Based on Natera’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $33.82 million. In comparison, last year the company had a GAAP net loss of $27.73 million.
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Natera, Inc. engages in the discovery, development, and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test, Horizon Carrier Screening, Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis, Anora Products of Conception, and Non-Invasive Paternity Testing.
